Close
Almac
Achema middle east

$15m Mitochondrial Clinical Trial Headed by Australian University

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
- Advertisement -

Almost 50 children in Australia are born every year with a devastating mitochondrial disease that has an expected lifespan of just 5 years. In a first in Australia, the Medical Research Future Fund has gone on to announce $15 million in funding, which also happens to be only the second in the world when it comes to clinical trials of mitochondrial donation.

The mitochondrial DNA is inherited through the mother’s egg and is responsible when it comes to helping mitochondria generate energy across all the body’s cells. Apparently, if the mitochondrial DNA carries variants that lead to energy production that is indeed faulty, mitochondrial disease can be caused.

Mitochondrial donations look forward to rectifying this genetic timebomb through an assisted reproductive technology form under which the future baby’s mitochondrial DNA is available from a donor’s egg so as to avoid the passing of the torch when it comes to inherited mitochondrial disease.

The mitoHOPE, which stands for Healthy Outcomes Pilot and Evaluation Programme, has in it mitochondrial as well as clinical geneticists from across the country, as well as fertility specialists and clinical embryologists from Monash IVF, who happen to be working together with Monash University’s and the University of Adelaide’s reproductive scientists.

It is well to be noted that the trial, which happens to be based in Melbourne in partnership with Monash, is going to be available for all the eligible women from across the country.

Apparently, the success of the mitoHOPE programme will be completely dependent on the Australian women’s willingness when it comes to donating eggs for reproductive purposes and also for research use so as to make improvements in the technical procedures.

Latest stories

Related stories

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »